Pharmaceutical research and development: what do we get for all that money?
Authors:
Abstract
Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing onesKeywords
This publication has 20 references indexed in Scilit:
- International comparison of assessments of pharmaceutical innovationHealth Policy, 2012
- Superior efficacy of new medicines?European Journal of Clinical Pharmacology, 2010
- Policy Making on Data Exclusivity in the European Union: From Industrial Interests to Legal RealitiesJournal of Health Politics, Policy and Law, 2009
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- The myth of the biotech revolution: An assessment of technological, clinical and organisational changeResearch Policy, 2007
- An update on the first decade of the European centralized procedure: how many innovative drugs?British Journal of Clinical Pharmacology, 2006
- Foreign free riders and the high price of US medicinesBMJ, 2005
- “Breakthrough” drugs and growth in expenditure on prescription drugs in CanadaBMJ, 2005
- Keynote review: Is declining innovation in the pharmaceutical industry a myth?Drug Discovery Today, 2005
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003